Literature DB >> 17178292

Can pelvic radiotherapy be omitted in select patients with rectal cancer?

Lily L Lai1, Clifton D Fuller, Lisa A Kachnic, Charles R Thomas.   

Abstract

Randomized prospective trials have shown the benefits of adjuvant radiotherapy in decreasing local recurrence rates in stage II and stage III rectal cancer. However, some patients with stage II lesions have relatively low risks of local recurrence when treated with modern surgery alone. This article will discuss important prognostic, diagnostic, and therapeutic factors including depth of tumor invasion, tumor location, improvements in staging with endorectal ultrasound and magnetic resonance imaging, enhanced surgical technique with total mesorectal excision, circumferential tumor margin, and lymph node dissection that may help to better define a subset of stage II rectal cancer patients in which pelvic radiation may be safely omitted.

Entities:  

Mesh:

Year:  2006        PMID: 17178292     DOI: 10.1053/j.seminoncol.2006.10.019

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  13 in total

1.  Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial?

Authors:  Jin Soo Kim; Nam Kyu Kim; Byung Soh Min; Hyuk Hur; Joong Bae Ahn; Ki Chang Keum
Journal:  Int J Colorectal Dis       Date:  2010-06-11       Impact factor: 2.571

Review 2.  Radiotherapy for Colorectal Cancer: Current Standards and Future Perspectives.

Authors:  Matthias F Häfner; Jürgen Debus
Journal:  Visc Med       Date:  2016-06-16

3.  Physicians' beliefs about the benefits and risks of adjuvant therapies for stage II and stage III colorectal cancer.

Authors:  Anthony C Wong; Shannon Stock; Deborah Schrag; Katherine L Kahn; Talya Salz; Mary E Charlton; Selwyn O Rogers; Karyn A Goodman; Nancy L Keating
Journal:  J Oncol Pract       Date:  2014-07-01       Impact factor: 3.840

4.  Identification of patient subgroups with low risk of postoperative local recurrence for whom total mesorectal excision surgery alone is sufficient: a multicenter retrospective analysis.

Authors:  Takehito Yamamoto; Kenji Kawada; Ryo Matsusue; Shigeru Kato; Yoshiro Itatani; Koya Hida; Takafumi Machimoto; Takashi Yamaguchi; Kazutaka Obama
Journal:  Int J Colorectal Dis       Date:  2022-09-26       Impact factor: 2.796

5.  Surgeon-Level Variation in Utilization of Local Staging and Neoadjuvant Therapy for Stage II-III Rectal Adenocarcinoma.

Authors:  Douglas S Swords; David E Skarda; William T Sause; Ute Gawlick; George M Cannon; Mark A Lewis; Courtney L Scaife; Jesse A Gygi; H Tae Kim
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

6.  Local recurrence after laparoscopic resection of T3 rectal cancer without preoperative chemoradiation and a risk group analysis: an Asian collaborative study.

Authors:  Sun-Il Lee; Seon-Hahn Kim; Hwei-Ming Wang; Gyu-Seog Choi; Min-Hua Zheng; Masaki Fukunaga; Jun-Gi Kim; Wai Lun Law; Joe-Bin Chen
Journal:  J Gastrointest Surg       Date:  2007-10-24       Impact factor: 3.452

7.  Outcome of patients with clinical stage II or III rectal cancer treated without adjuvant radiotherapy.

Authors:  Shin Fujita; Seiichiro Yamamoto; Takayuki Akasu; Yoshihiro Moriya
Journal:  Int J Colorectal Dis       Date:  2008-07-02       Impact factor: 2.571

Review 8.  The Selective Use of Radiation Therapy in Rectal Cancer Patients.

Authors:  Andrew Martella; Christopher Willett; Manisha Palta; Brian Czito
Journal:  Curr Oncol Rep       Date:  2018-04-11       Impact factor: 5.075

9.  A magnetic resonance imaging (MRI)-based nomogram for predicting lymph node metastasis in rectal cancer: a node-for-node comparative study of MRI and histopathology.

Authors:  Yuan Liu; Lijuan Wan; Wenjing Peng; Shuangmei Zou; Zhaoxu Zheng; Feng Ye; Jun Jiang; Han Ouyang; Xinming Zhao; Hongmei Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-06

10.  Prognostic nomograms for predicting survival and distant metastases in locally advanced rectal cancers.

Authors:  Junjie Peng; Ying Ding; Shanshan Tu; Debing Shi; Liang Sun; Xinxiang Li; Hongbin Wu; Sanjun Cai
Journal:  PLoS One       Date:  2014-08-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.